Mechanisms of resistance to CAR T cell therapies

Semin Cancer Biol. 2020 Oct:65:91-98. doi: 10.1016/j.semcancer.2019.12.002. Epub 2019 Dec 19.

Abstract

Chimeric antigen receptor (CAR)-engineered T cells have demonstrated remarkable success in the treatment of B cell malignancies. FDA approval of these therapies represents a watershed moment in the development of therapies for cancer. Despite the successes of the last decade, many patients will unfortunately not experience durable responses to CAR therapy. Emerging research has shed light on the biology responsible for these failures, and further highlighted the hurdles to broader success. Here, we review the recent research identifying how interactions between cancer cells and engineered immune cells result in resistance to CAR therapies.

Keywords: Chimeric antigen receptor; Resistance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Drug Resistance, Neoplasm / immunology*
  • Humans
  • Immunotherapy, Adoptive / adverse effects*
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Receptors, Chimeric Antigen / immunology*
  • Receptors, Chimeric Antigen / therapeutic use
  • T-Lymphocytes / immunology

Substances

  • Receptors, Chimeric Antigen